Advanced Therapy Medicinal Products Market to Reach Approximately USD 149.24 Billion by 2033 as Gene Therapy Expansion, Cell Therapy Adoption, and Pipeline Maturity Accelerate Global Commercial Growth

May 3, 2026 - The global Advanced Therapy Medicinal Products (ATMP) market was estimated at USD 27.04 billion in 2022 and, based on the stated 16.8% CAGR, is estimated at approximately USD 43.09 billion in 2025 and projected to reach about USD 149.24 billion in 2033. The published outlook already indicated a rise to USD 90.98 billion by 2030, and the 2033 figure used here is an extrapolated continuation of the same growth rate beyond that horizon. That implies an incremental revenue opportunity of roughly USD 106.15 billion between 2025 and 2033, highlighting how quickly advanced therapies are moving from niche, high-complexity medicine into a larger commercial treatment category.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/advanced-therapy-medicinal-product-atmp-market?kailas

The market is being driven by a powerful convergence of factors: broader clinical acceptance of gene and cell therapies, rising investment in rare disease and oncology programs, and increasing willingness among large biopharma companies to scale one-time or highly individualized treatments. Recent regulatory and clinical momentum supports that view. In April 2026, Novartis announced a positive CHMP opinion for Itvisma for spinal muscular atrophy in the European Union, potentially expanding gene replacement therapy into an older patient population. In April 2026, Kite also received full FDA approval for Tecartus in adult patients with relapsed or refractory mantle cell lymphoma. These events matter commercially because they show ATMPs progressing beyond early proof of concept and into broader label expansion, lifecycle development, and deeper physician adoption.

Recent Developments

1. In April 2026, Novartis said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Itvisma in spinal muscular atrophy. Novartis stated that, if approved, Itvisma could become the first and only gene replacement therapy for children two years and older, teens, and adults with SMA in the European Union. This matters because it signals continued expansion of gene therapy beyond the earliest pediatric cohorts and into larger patient populations.

2. In April 2026, Kite announced that the U.S. FDA granted full approval to Tecartus for adult patients with relapsed or refractory mantle cell lymphoma. This is commercially important because full approval strengthens the role of autologous cell therapy in hematologic oncology and reinforces the long-term market depth of ATMPs in cancer treatment.

3. In April 2026, Novartis also said it finalized a U.S. manufacturing and R&D expansion plan with a seventh new facility. While this is broader than ATMPs alone, it is highly relevant because advanced therapies depend heavily on manufacturing control, scale-up capability, and supply-chain resilience, making production infrastructure a major competitive factor in the category.

4. In February 2026, Kite reported an FDA-approved label update for Yescarta for relapsed or refractory primary central nervous system lymphoma. The significance here is not just one product update. It shows the cell therapy market continuing to broaden its treated indications, which increases physician confidence and strengthens the commercial foundation for next-generation ATMP programs.

Segment Analysis

By type, gene therapy medicines are emerging as one of the most strategically important segments because they offer the possibility of one-time treatment for severe genetic disorders and are increasingly supported by more mature regulatory and manufacturing pathways. Novartis' Itvisma update and Orchard Therapeutics' continued focus on hematopoietic stem cell gene therapy both reinforce that gene therapy remains one of the clearest long-term value pools in ATMPs, particularly in rare disease and inherited disorders. In business terms, this segment matters because it combines high unmet need, premium pricing potential, and strong differentiation from chronic standard-of-care models.

At the same time, somatic cell therapy medicines remain one of the most commercially established segments, especially in oncology. Kite's Tecartus approval and Bristol Myers Squibb's earlier expansion of Abecma in the European Union show that cell therapies continue to deepen their clinical position in hematologic malignancies. In practical terms, cancer remains one of the most monetizable disease indications in ATMPs because relapse-driven treatment needs, specialist-center delivery models, and high-value reimbursement environments align well with these therapies' complexity.

Regional Analysis

The United States remains the leading commercial market because it combines the deepest advanced-therapy pipeline, a strong reimbursement base for high-value oncology and rare disease products, and large-scale manufacturing investment. Novartis' newly finalized U.S. expansion plan and Kite's latest FDA approval both reinforce the strength of the U.S. ecosystem for commercialization, regulatory progression, and facility buildout. These are not direct U.S. market-size figures, but they are strong structural indicators that the country remains the primary growth engine for ATMP adoption.

Japan is strategically important because it continues to emphasize regenerative medicine and advanced cell therapy as part of its broader healthcare innovation agenda. Public company activity also supports that view. CYFUSE Biomedical, based in Japan, continues to position its Bio 3D printing platform around regenerative medicine applications, showing that Japan remains relevant not only as an end market but also as an innovation base for advanced therapeutic technologies. In practical terms, Japan matters because it combines translational healthcare interest with a strong institutional focus on next-generation therapies, even where direct public market-size data for ATMPs is limited.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=advanced-therapy-medicinal-product-atmp-market?kailas

Company Profiles

Novartis Europharm Limited remains one of the most important companies in the ATMP landscape because it continues to advance gene therapy programs in serious neurological disease. Its April 2026 positive CHMP opinion for Itvisma shows ongoing lifecycle development in gene replacement therapy and highlights why Novartis matters commercially: it has the scale to pair clinical innovation with regulatory reach and manufacturing investment.

Kite Pharma EU B.V. remains one of the clearest commercial leaders in cell therapy. Its April 2026 full FDA approval for Tecartus reinforces Kite's strength in hematologic oncology and underscores the commercial durability of autologous CAR-T as one of the most established ATMP formats in the market today.

Orchard Therapeutics plc. is strategically important because it is focused specifically on hematopoietic stem cell gene therapy and positions its portfolio around severe genetic diseases. Orchard matters because it represents the part of the ATMP market centered on curative potential in ultra-rare and inherited conditions, where long-term value can be significant even with relatively small patient populations.

Bristol-Myers Squibb Pharma EEIG remains relevant through its continued presence in cell therapy, including the earlier EU expansion of Abecma for multiple myeloma. That matters because it shows major oncology players continuing to build out advanced therapy franchises in commercially important hematologic settings.

Analyst View

The strongest revenue pools in the ATMP market are forming where high unmet need, premium clinical value, and scalable manufacturing capability intersect. That makes gene therapy medicines, somatic cell therapy medicines, and oncology and rare disease indications the most attractive commercial segments over the medium term. These are the areas where therapeutic differentiation is clearest and where payers are more willing to engage with high-value treatment models if outcomes are compelling.

Competition is also becoming more sophisticated. The likely winners will not be defined only by breakthrough science, but by their ability to expand labels, secure regulatory confidence, scale production, and support patient access in real-world healthcare systems. In this market, the next phase of value creation will come from making advanced therapies easier to manufacture, easier to deliver, and broader in clinical reach without losing their curative promise.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.